ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 739

Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study

Yair Molad1,2, Mohammad Egbaria3, Ariela Dortort-Lazar4,5, Elisheva Pokroy-Shapira3,5, Shirly Oren4, Yonatan Edel3,5 and Vitaly Kliminski5,6, 1Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, 2Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 3Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 4Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Activity score, Biomarkers, Lupus nephritis, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary and plasma levels of sTREM-1 in evaluating disease activity in patients with active renal and non-renal SLE.

Methods:

15 patients with active renal lupus (ARL), 15 patients with active non-renal lupus (ANRL), and 30 patients with inactive lupus (IL), defined by baseline score of Safety of Estrogen in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) ≥ or < 6 and renal-SLEDAI ≥ 4 or 0. Urine and plasma samples were collected and kept at -70°c until assayed for sTREM-1 levels using commercial ELISA. Urinary values were normalized for creatinine (Cr.) excretion. Plasma and urine samples of healthy individuals served as healthy control (HC).

Results:

Compared to HC (urine: n=13; plasma: n =72), baseline mean urine sTREM-1 level (UsTREM-1) was significantly higher in ARL (62.38±85.14pg/mg Cr. vs. 3.05±7.19 pg/mg Cr., p=0.0015) but not in ANRL, whereas plasma sTREM-1 (PsTREM-1) was significantly higher in patients with ANRL (361.47±187.79pg/ml, 312.15pg/ml vs. 228.76±85.23pg/ml, p=0.009) and not in the ARL group. Moreover, UsTREM-1 level significantly discriminated between ALN and ANRL or IL (p=0.0056) as well as the ratio of urine-to-plasma sTREM-1 (p=0.0083), whereas PsTREM-1 was significantly higher in ANRL compared to ARL or IL (p=0.014). Baseline SELENA-SLEDAI score correlated with UsTREM-1 (p=0.0005) and PsTREM-1 (p=0.006) while renal-SLEDAI correlated only with UsTREM-1 (p=0.013). Elevated UsTREM-1 level positively correlated with higher ESR (r=0.35, p=0.03), serum anti-dsDNA antibody titer (r=0.39, p=0.006), SELENA-SLEDAI and renal-SLEDAI scores (r=0.48, p=0.0005 and r=0.36, p=0.013, respectively) and inversely correlated with lower serum C3 level (r=-0.39, p=0.005). Elevated PsTREM-1 level positively correlated with age (r=0.25, p=0.005), serum creatinine (r=0.33, p=0.0006), higher ESR (r=0.4, p=0.007), serum anti-dsDNA antibody (r=0.59, p<0.0001) and SELENA-SLEDAI score (r=0.38, p=0.006) but not with renal-SLEDAI score and serum C3 and C4 levels. Receiver operating characteristic (ROC) curves analysis of the area under the curve (AUC) displays that PsTREM-1 level differentiates between overall active SLE and IL: AUC = 0.74, 95%CI 1.001 – 1.010, p=0.01.

Conclusion:

Our data suggest that UsTREM-1 level correlates with ARL while elevated PsTREM-1 correlates with ANRL. Urine and plasma sTREM-1 might be clinically used as a biomarker for the assessment of renal and non-renal disease activity in SLE. We suggest that renal innate immune activation and particularly TREM-1 play a role in the pathogenesis of lupus nephritis.


Disclosure: Y. Molad, None; M. Egbaria, None; A. Dortort-Lazar, None; E. Pokroy-Shapira, None; S. Oren, None; Y. Edel, None; V. Kliminski, None.

To cite this abstract in AMA style:

Molad Y, Egbaria M, Dortort-Lazar A, Pokroy-Shapira E, Oren S, Edel Y, Kliminski V. Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/urine-and-plasma-soluble-triggering-receptor-expressed-on-myeloid-cells-1-strem-1-differentially-correlates-with-renal-and-non-renal-systemic-lupus-erythematosus-sle-a-prospective-case-control-s/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urine-and-plasma-soluble-triggering-receptor-expressed-on-myeloid-cells-1-strem-1-differentially-correlates-with-renal-and-non-renal-systemic-lupus-erythematosus-sle-a-prospective-case-control-s/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology